CA2557433C - Derives de quinazoline et leur utilisation therapeutique - Google Patents

Derives de quinazoline et leur utilisation therapeutique Download PDF

Info

Publication number
CA2557433C
CA2557433C CA2557433A CA2557433A CA2557433C CA 2557433 C CA2557433 C CA 2557433C CA 2557433 A CA2557433 A CA 2557433A CA 2557433 A CA2557433 A CA 2557433A CA 2557433 C CA2557433 C CA 2557433C
Authority
CA
Canada
Prior art keywords
group
compound
fluorophenyl
tumors
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2557433A
Other languages
English (en)
Other versions
CA2557433A1 (fr
Inventor
Young Bok Lee
Chang Ho Ahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rexahn Corp
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2557433(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of CA2557433A1 publication Critical patent/CA2557433A1/fr
Application granted granted Critical
Publication of CA2557433C publication Critical patent/CA2557433C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des dérivés de quinazoline, représentés par la formule générale: leurs sels pharmalogiquement acceptables, et des compositions comprenant ces composés. L'invention concerne des procédés destinés au traitement de troubles hyperprolifératifs.
CA2557433A 2004-02-19 2005-02-17 Derives de quinazoline et leur utilisation therapeutique Expired - Fee Related CA2557433C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54548704P 2004-02-19 2004-02-19
US60/545,487 2004-02-19
PCT/US2005/005151 WO2005080352A2 (fr) 2004-02-19 2005-02-17 Derives de quinazoline et leur utilisation therapeutique

Publications (2)

Publication Number Publication Date
CA2557433A1 CA2557433A1 (fr) 2005-09-01
CA2557433C true CA2557433C (fr) 2013-05-14

Family

ID=34886161

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2557433A Expired - Fee Related CA2557433C (fr) 2004-02-19 2005-02-17 Derives de quinazoline et leur utilisation therapeutique

Country Status (11)

Country Link
US (2) US7388014B2 (fr)
EP (2) EP1720841B1 (fr)
JP (1) JP4934432B2 (fr)
KR (1) KR100942865B1 (fr)
CN (1) CN1956966B (fr)
AU (1) AU2005214373B2 (fr)
BR (1) BRPI0507903A (fr)
CA (1) CA2557433C (fr)
ES (1) ES2554330T3 (fr)
MX (1) MXPA06009475A (fr)
WO (1) WO2005080352A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5237798B2 (ja) * 2005-06-23 2013-07-17 アレイ バイオファーマ、インコーポレイテッド ベンズイミダゾール化合物の調製方法
WO2007133773A2 (fr) * 2006-05-15 2007-11-22 Senex Biotechnology, Inc Identification d'inhibiteurs de voie des cdki
WO2008124823A1 (fr) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Méthode de traitement du mélanome
CN101120945B (zh) * 2007-07-30 2010-11-24 浙江大学 8-芳胺基-3H-咪唑[4,5-g]喹唑啉类衍生物的用途
PH12012500097A1 (en) * 2009-07-21 2011-01-27 Shanghai Inst Organic Chem Potent small molecule inhibitors of autophagy, and methods of use thereof
AU2011278832B2 (en) * 2010-07-14 2014-03-13 Betta Pharmaceuticals Co., Ltd Novel fused heterocyclic derivatives useful as c-Met tyrosine kinase inhibitors
SG11201401343YA (en) * 2011-09-13 2014-08-28 Igor Roninson TREATMENT OF DISEASE OR DISORDERS CAUSED BY INDUCED NFkB TRANSCRIPTIONAL ACTIVITY
CN103086984A (zh) * 2011-11-03 2013-05-08 南京大学 一类4-苯氨基喹唑啉类衍生物及其制备方法与用途
US9462809B2 (en) 2012-03-13 2016-10-11 Basf Se Fungicidal pyrimidine compounds
CN102659692B (zh) 2012-05-04 2014-04-09 郑州泰基鸿诺药物科技有限公司 双联厄洛替尼及其制备方法
CN102875570B (zh) * 2012-10-23 2015-11-04 浙江大学 喹唑啉衍生物及其制备方法和用途
MX367420B (es) 2013-03-14 2019-08-21 Convergene Llc Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
WO2015036059A1 (fr) 2013-09-16 2015-03-19 Basf Se Composés fongicides de pyrimidine
RU2016112013A (ru) * 2013-09-19 2017-10-24 Пьер Фабр Медикамент Производные хиназолина и их применение в качестве ингибиторов днк-метилтрансферазы
CN104926798B (zh) * 2014-03-21 2019-06-18 江苏豪森药业集团有限公司 阿法替尼中间体的高纯度制备方法
AU2016361441B2 (en) * 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
US10953016B2 (en) * 2017-01-30 2021-03-23 Shionogi & Co., Ltd. Solid dosage form containing quinazoline derivative
JP2022514692A (ja) * 2018-12-21 2022-02-14 ユニバーシティ・オブ・ノートル・ダム・デュ・ラック 抗酸菌症治療のためのｂｄオキシダーゼ阻害剤の発見
JP7178291B2 (ja) 2019-02-26 2022-11-25 日本製鉄株式会社 ガス供給管カプラの締結解除機構
KR102397359B1 (ko) * 2019-09-30 2022-05-11 한국화학연구원 4-아미노-퀴나졸린 유도체 및 이를 포함하는 항바이러스용 조성물
WO2022222875A1 (fr) * 2021-04-19 2022-10-27 昆药集团股份有限公司 Dérivé tricyclique de benzopyrimidine, son procédé de préparation et son utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH492395A (de) 1966-04-26 1970-06-30 Sandoz Ag Mittel zur Bekämpfung von Pflanzenschädlingen und Verwendung des Mittels
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU5108196A (en) * 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
EP0817775B1 (fr) * 1995-03-30 2001-09-12 Pfizer Inc. Derives de quinazoline
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
CA2258548C (fr) * 1996-06-24 2005-07-26 Pfizer Inc. Derives tricycliques substitues par phenylamino, destines au traitement des maladies hyperproliferatives
HUP9900790A3 (en) * 1996-08-30 2001-11-28 Kyowa Hakko Kogyo Kk Imidazoquinazoline derivatives
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
AU779695B2 (en) * 2000-04-07 2005-02-10 Astrazeneca Ab Quinazoline compounds
DE10042060A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6653305B2 (en) * 2000-08-26 2003-11-25 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them

Also Published As

Publication number Publication date
US20090030021A1 (en) 2009-01-29
EP1720841A2 (fr) 2006-11-15
EP1720841B1 (fr) 2015-11-04
AU2005214373B2 (en) 2011-07-28
CA2557433A1 (fr) 2005-09-01
ES2554330T3 (es) 2015-12-18
WO2005080352A2 (fr) 2005-09-01
JP2007523177A (ja) 2007-08-16
MXPA06009475A (es) 2007-05-15
US20050187231A1 (en) 2005-08-25
AU2005214373A1 (en) 2005-09-01
US8404698B2 (en) 2013-03-26
WO2005080352A3 (fr) 2006-02-16
CN1956966A (zh) 2007-05-02
US7388014B2 (en) 2008-06-17
KR20070028340A (ko) 2007-03-12
EP2650286A1 (fr) 2013-10-16
CN1956966B (zh) 2012-04-18
BRPI0507903A (pt) 2007-07-10
JP4934432B2 (ja) 2012-05-16
KR100942865B1 (ko) 2010-02-17

Similar Documents

Publication Publication Date Title
CA2557433C (fr) Derives de quinazoline et leur utilisation therapeutique
JP6275153B2 (ja) ヘテロ環式グルタミナーゼ阻害剤
EP3148536B1 (fr) Associations pharmaceutiques pour traiter le cancer
US20200055838A1 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
EA036453B1 (ru) Замещенные производные 2-анилинпиримидина в качестве модуляторов egfr
NZ535990A (en) Angiogenesis inhibitors
AU2006236940A1 (en) Use of an epidermal growth factor receptor kinase inhibitor (EGFR) in gefitinib resistant patients
KR20140096375A (ko) 항종양제의 효과 증강제
WO2009047298A2 (fr) Dimères de harmol ou de ses dérivés et leurs utilisations
JP2007510667A (ja) 癌の治療法
US20170015672A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
CA3195465A1 (fr) Succinate et sa forme cristalline utilises en tant qu'agents therapeutiques
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
WO2012154879A2 (fr) Inhibiteurs d'autophagie
CN102532020A (zh) 作为抗肿瘤剂的5、6或7-取代-3-(杂)芳基-异喹啉胺衍生物
WO2007132221A1 (fr) Inhibiteurs de la kinase aurora à base de pyrimidine-thiazole, anticancéreux, combinés
TW201636345A (zh) 具抗腫瘤活性之化合物
KR101693326B1 (ko) 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 복합제
CN112843059A (zh) 一种取代丁烯酰胺的应用
EP2439194A1 (fr) Diamides phényl et préparation pharmaceutique comprenant des diamides phényl
US20210221800A1 (en) Crystalline compounds and methods of making the same
CN116751162A (zh) 一种喹啉类化合物、其制备方法、药物组合物及医药用途
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200217